Diabetes & Endocrinology
A major trial demonstrated the glucose-lowering drug empagliflozin reduces cardiovascular morbidity and mortality in individuals with Type 2 diabetes and existing cardiovascular disease. Clinicians and researchers discuss how it does so and who is most likely to benefit.
The immune systems of mice can “remember” cancer cells and provide extended immunity, according to research involving technology that carries individualized vaccines to treat certain tumors.
University of Michigan researchers filled nanodiscs — tiny...
Not all plant-based foods provide equal benefit in terms of reducing risk of diabetes, a new Harvard study finds.
Bariatric surgery continues to proliferate — and that has significant implications for surgeons who perform the procedures, for physicians who treat obesity-related comorbidities and for plastic surgeons.
Two types of bariatric surgery were markedly more effective than lifestyle interventions alone at producing at least partial remission of Type 2 diabetes, according to a recent study. The findings add to the evidence of weight-loss surgery’s effectiveness as a diabetes treatment for certain individuals.
Using an experimental synthetic ROR inverse agonist, SR1001, a team of researchers prevented mouse models from developing Type 1 diabetes.
Learn how illnesses that require long-term management are on the rise — and the impact that is having on healthcare costs.
A quality-improvement initiative in Texas sheds light on strategies for providing enhanced care to patients with diabetes.
These devices in the works may enhance disease detection, dietary tracking and infant incubation.
- 1 of 2
- next ›